163706-06-7

Anti-platelet agent.

ChEBI: A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.

Direct P2Y12 platelet receptor antagonist:

Antiplatelet for patients undergoing a PCI

Potentially hazardous interactions with other drugs
None known

Cangrelor is deactivated rapidly in the plasma by dephosphorylation to form its main metabolite, a nucleoside. Following a 2 micrograms/kg/min infusion of [3 H] cangrelor, 58% was found in urine and the remaining 35% was found in faeces, presumably following biliary excretion.